OmniAb entered into a technology license and services agreement with Mabtrx Biosciences, a wholly‑owned subsidiary of the joint venture between ArrowMark Partners and Viking Global Investors, on November 18 2025. The deal grants OmniAb the right to provide antibody discovery services and to receive revenue for services performed, with additional potential equity and royalty payments for novel antibody programs developed for Mabtrx’s defined targets.
The partnership leverages OmniAb’s transgenic chicken‑based discovery platform, positioning the company to deliver high‑value antibodies to a new venture‑backed partner. It marks OmniAb’s first collaboration with a newly‑formed incubated company, expanding its partner network and adding a new source of service revenue and future royalty upside.
OmniAb’s recent financial performance has been challenging, with declining revenue and net losses in the most recent quarters. The new agreement therefore represents a significant diversification of revenue streams and a potential catalyst for future profitability, aligning with the company’s strategy of generating long‑term cash flows from partner‑led product development.
The terms of the agreement include revenue for services performed and potential equity and royalty payments for novel antibody programs. Specific financial figures and royalty rates were not disclosed, and Mabtrx’s therapeutic targets remain confidential.
ArrowMark and Viking bring a history of successful biotech investments. CEO Matt Foehr said the partnership reflects confidence in OmniAb’s technology and its ability to address next‑generation drug targets. Tony Yao of ArrowMark noted that OmniAb’s platform can support a range of therapeutic strategies.
The joint venture that owns Mabtrx is named AMVKG LS. OmniAb’s most recent quarterly revenue declined, and the company remains unprofitable for the next three years, underscoring the importance of new revenue streams such as this partnership.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.